About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Drug-Drug Interaction Study in Healthy Subjects | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT00904059

Drug-Drug Interaction Study in Healthy Subjects

The purpose of this study is to assess the pharmacokinetics and safety of BMS-790052 and BMS-650032 when co-administered and when administered alone

Lead sponsor: Bristol-Myers Squibb•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Bristol-Myers Squibb

Pharmacokinetics and Safety in Healthy Subjects

Age

18 - 49 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy male and female subjects aged 18 to 49 years
•Females who are not of childbearing potential, pregnant or breastfeeding
•Subject Body Mass Index (BMI) of 18 to 32 kg/m²

Exclusion Criteria

•Women of child bearing potential
•Male subjects who have sex with women who are unwilling to agree to practice male barrier contraception during study participation and for a least 12 weeks following dosing
•Any significant acute or chronic medical illness
•Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
•Prior exposure to BMS-650032 or BMS-790052
•Positive for HIV or HCV

Related studies

RECRUITINGPhase 4

Implementing Low-Barrier HCV Treatment in a Jail Setting

NCT06953479 · HEPATITIS C (HCV), Incarceration, and more

Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum

NCT04162938 · Hepatitis C

Project I Test: Implementing HIV Testing in Opioid Treatment Programs

NCT03135886 · HIV/AIDS, Hepatitis C, and more

Persuasive Health Communication Intervention for HIV/HCV

NCT05968573 · Human Immunodeficiency Virus (HIV), Hepatitis C (HCV)

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

NCT01644903 · Liver Transplant, Hepatitis C, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 7, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment28

Start dateMay 2009

Last updatedJan 7, 2011

Condition

Locations shown

Ppd Development, Lp

Austin, Texas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 7, 2011Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions